Chargement en cours...
Novel agents and immune invasion in Hodgkin lymphoma
The approval of brentuximab vedotin (BV) and the PD-1 inhibitors nivolumab and pembrolizumab has dramatically improved outcomes for patients with relapsed or refractory (R/R) classic Hodgkin lymphoma (HL). With the goal of increasing long-term disease control rates and decreasing late toxicities, th...
Enregistré dans:
| Publié dans: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Hematology
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913426/ https://ncbi.nlm.nih.gov/pubmed/31808827 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000029 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|